This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BARDA And Emergent BioSolutions Partner To Establish Center For Innovation In Advanced Development And Manufacturing

Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into a public-private partnership with the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services (HHS), to establish a Center for Innovation in Advanced Development and Manufacturing (Center). The Center will facilitate advanced development of chemical, biological, radiological, and nuclear (CBRN) medical countermeasures, ensure domestic pandemic influenza vaccine manufacturing surge capacity, share facility construction costs, and provide workforce development training programs to address the U.S. government’s preparedness priorities and needs.

“Emergent is pleased to enter into this long-term public-private partnership with BARDA to help achieve our common goal of strengthening national security and preparedness efforts,” said Daniel J. Abdun-Nabi, president and chief executive officer of Emergent BioSolutions. “We are honored by the U.S. government’s continued confidence in us, which is founded on our longstanding track record of being the premier biodefense developer and supplier of medical countermeasures. This award underscores Emergent’s core competencies not only in product development and manufacturing, but also our expertise in contracting with the U.S. government and navigating the regulatory process. This partnership truly allows us the opportunity to fulfill our mission – to protect life.”

The contract consists of an eight-year cost-reimbursable, cost-share base period of performance, with a fixed price component, valued at approximately $220 million, with up to 17 additional 1-year options that will specify their own period of performance and contract value. The eight-year base period of performance includes:
  • Securing a pandemic influenza vaccine candidate and obtaining access to all necessary Intellectual Property rights for facility process development and manufacturing,
  • Constructing additional facilities to support pandemic influenza vaccine production, and
  • Obtaining facility licensure to manufacture a pandemic influenza vaccine at the Baltimore facility.

Under the contract, BARDA may issue service task orders for requirements such as CBRN advanced development, pandemic influenza vaccine surge production, facility readiness, and other activities including bulk manufacturing, formulation, filling and finishing, storage, and shipping.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs